Note: This variant has not been sufficiently evaluated by a GET-Evidence editor.
To be considered sufficiently evaluated a variant must have both "variant evidence" and "clinical importance" scores filled in.
Please help improve GET-Evidence by evaluating evidence for this variant!
You are viewing an old version of this page that was saved on December 29, 2011 at 4:57pm by Madeleine Ball.
Insufficiently evaluated pathogenic
(The "insufficiently evaluated" qualifier is assigned automatically based on the above evidence and importance scores.)
Summary of published research, and additional commentary
Added in this revision:
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou
GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome
Project. Acquired mutation of the tyrosine kinase JAK2 in human
myeloproliferative disorders. Lancet. 2005 Mar 19-25;365(9464):1054-61. Erratum
in: Lancet. 2005 Jul 9-15;366(9480):122. PubMed PMID: 15781101.